← Back to Search

Other

Exposure-Based Therapy for Anxiety Disorders

Verified Trial
N/A
Recruiting
Led By Michael Otto, Ph.D.
Research Sponsored by University of Texas at Austin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are you able to attend 12 weekly in-person sessions at the University of Texas at Austin?
Do you have a diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder?
Must not have
Do you have any of the following: cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke?
Are you currently pregnant or lactating?
Timeline
Screening 1 day
Treatment 12 weeks
Follow Up 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is designed to see if a new biomarker can help predict which patients will respond to exposure-based therapy for anxiety, OCD and stress-related disorders.

Who is the study for?
Adults aged 18-70 with anxiety, OCD, or PTSD who can consent and follow the study plan. They must speak English and have a certain level of anxiety. Those stable on meds for at least 8 weeks may join; however, people with bipolar/psychotic disorders, recent substance/eating disorders, serious cognitive issues, or conditions that make CO2 challenges unsafe cannot participate.
What is being tested?
The trial is testing if a simple CO2 challenge can predict who won't respond well to exposure-based therapy for various anxiety-related conditions. It aims to help clinicians decide whether this type of therapy should be started.
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects from the CO2 challenge could include shortness of breath, dizziness, increased heart rate or panic due to the sensation of suffocation which might trigger anxiety symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Timeline

Screening ~ 1 day
Treatment ~ 12 weeks
Follow Up ~3 months
This trial's timeline: 1 day for screening, 12 weeks for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Non-response to exposure-based therapy
Secondary study objectives
Clinical Global Impression - Severity of Illness (CGI-S)
Dimensional Obsessive-Compulsive Scale (DOCS)
GAD-7
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open Exposure-Based Therapy (EBT)Experimental Treatment1 Intervention
All participants will receive a well-established psychological treatment.

Find a Location

Who is running the clinical trial?

University of Texas at AustinLead Sponsor
378 Previous Clinical Trials
86,005 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
161 Patients Enrolled for Obsessive-Compulsive Disorder
Boston UniversityOTHER
478 Previous Clinical Trials
9,994,610 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,936 Previous Clinical Trials
2,741,413 Total Patients Enrolled
69 Trials studying Obsessive-Compulsive Disorder
14,752 Patients Enrolled for Obsessive-Compulsive Disorder
Michael Otto, Ph.D.Principal InvestigatorBoston University
Jasper Smits, Ph.D.Principal InvestigatorThe University of Texas at Austin
3 Previous Clinical Trials
132 Total Patients Enrolled

Media Library

Exposure-Based Therapy (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05467683 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Open Exposure-Based Therapy (EBT)
Obsessive-Compulsive Disorder Clinical Trial 2023: Exposure-Based Therapy Highlights & Side Effects. Trial Name: NCT05467683 — N/A
Exposure-Based Therapy (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05467683 — N/A
Obsessive-Compulsive Disorder Patient Testimony for trial: Trial Name: NCT05467683 — N/A
~287 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top